CPB203

CPB203 is a preclinical biologic candidate developed by Alephoson for the treatment of non-infectious uveitis (NIU), including both anterior and posterior forms. The drug is engineered using Alephoson's proprietary Cell-Penetrating Biologic (CPB) platform, which utilizes cell-penetrating peptides to facilitate the delivery of large therapeutic molecules across ocular barriers. This technology is designed to enable the administration of biologics to the eye via non-invasive routes, such as topical eye drops, potentially providing a more patient-friendly alternative to traditional intravitreal injections for treating inflammatory conditions of the eye.